Transderm Scop — Class II drug recall D-0133-2017
Terminated recall by Sandoz Inc, reported 2016-11-16, distributed in TN. Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine foll
| Recall number | D-0133-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sandoz Inc, Princeton, NJ, United States |
| Recall initiated | 2016-08-24 |
| Classified | 2016-11-09 |
| Reported by FDA | 2016-11-16 |
| Terminated | 2017-06-07 |
| Distributed | TN |
| Quantity | 42,740 cartons |
| NDC | 10019-0553-02, 10019-0553-88 |
| Lot numbers | FV5908, FX1520 |
| Expiration dates | 2018-06, 2018-09, 2018-12, 2019-01, 2019-02 |
Product
Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 24 patches Multi pack, Rx only, Marketed by Baxter Healthcare Cop/Novartis, Deerfield, IL 60015, Manufactured by:Alza Corporation, Vacaville, CA 95688 for Novartis Consumer Health Inc., Parsippany, NJ 07054
Reason for recall
Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0133-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.